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The enzymes isocitrate lyase (ICL) isoforms 1 and 2 are essential for Mycobacterium tuberculosis survival
within macrophages during latent tuberculosis (TB). As such, ICLs are attractive therapeutic targets for the
treatment of tuberculosis. However, there are few biophysical assays that are available for accurate kinetic
and inhibition studies of ICL in vitro. Herein we report the development of a combined NMR spectroscopy
and thermal shift assay to study ICL inhibitors for both screening and inhibition constant (IC50) measure-
ment. Operating this new assay in tandem with virtual high-throughput screening has led to the discovery
of several new ICL1 inhibitors.
Introduction
Tuberculosis (TB) is a high burden infectious disease that is
caused by Mycobacterium tuberculosis.1,2 In 2015, there were
over 10 million new TB cases and around 1.8 million TB-
related deaths.3 TB has a long latency period; once a human
is infected with M. tuberculosis, the bacteria may stay inactive
within macrophages for many years leading to a syndrome
that is known as latent TB.4–6 The environment inside macro-
phages is relatively hypoxic and lacking in external nutrients.
In order to survive under these conditions, M. tuberculosis is
able to simultaneously catabolise different carbon sources,
including fatty acids and cholesterol that are available in rela-
tive abundance inside macrophages.7–9 The enzymes iso-
citrate lyase (ICL) isoforms 1 and 2 play essential roles in this
metabolic adaptation.10 ICLs are key enzymes in both the
M. tuberculosis glyoxylate and methylcitrate cycles. In the
glyoxylate cycle, ICLs catalyse the conversion of the tricarbox-
ylic acid (TCA) cycle intermediate isocitrate into glyoxylate
and succinate (Fig. 1a), thus bypassing the two decarboxyl-
ation steps in the TCA cycle and preserving these carbons for
gluconeogenesis.11,12 In the methylcitrate cycle, ICLs catalyse
the conversion of methylisocitrate, an intermediate of the
propionate degradation pathway, to pyruvate and succinate.
Propionate, which is toxic to the bacteria, is generated by
β-oxidation of odd chain fatty acids and cholesterol that M.
tuberculosis may utilise as carbon sources.12,13
Given the pivotal roles ICLs play in the survival of M. tu-
berculosis inside macrophages, ICLs are attractive inhibition
targets for the treatment of latent TB.14–16 We recently insti-
gated a research programme aimed at identifying new inhibi-
tors of ICLs, but it was readily apparent that few accurate bio-
physical assays are available to study ICL kinetics and
inhibition in vitro. Most ICL assays rely on ultraviolet/visible
(UV/vis) spectrophotometry to determine the amount of
glyoxylate that is formed as a result of ICL-catalysed reac-
tions. For example, one method uses lactate dehydrogenase
(LDH) to catalyse the reduction of glyoxylate to glycolate, dur-
ing which NADH (a cosubstrate of LDH) is oxidised to NAD+.
The decrease in NADH concentration is then measured by
UV/vis spectrophotometry using a tetrazolium/formazan
dye.17 Another method relies on the reaction phenylhydrazine
with glyoxylate to form a hydrazone, which is subsequently
analysed by UV/vis spectrophotometry.18 In addition to ki-
netic assays, the use of native non-denaturing mass spectro-
metry and intrinsic protein fluorescence to monitor ICL-
inhibitor binding interactions have also been reported.19
However, these assays have several drawbacks. Auto-oxidation
of NADH to NAD+ may affect the accuracy of the LDH-
coupled assay.20 In addition, this method is not suitable for
measuring the methylisocitrate lyase activity of ICLs because
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LDH cannot take pyruvate as substrate.20 For the
phenylhydrazine-coupled assay, the accuracy of the assay may
be compromised by the rate of the glyoxylate-
phenylhydrazone complex formation, which is pH dependent
and gets slower above pH 7.21,22 Phenylhydrazine is also un-
stable at pH 7 and above, with the breakdown products may
lead to a slow increase in the UV absorption, thus affecting
the accuracy of the measurements.21,22
1H nuclear magnetic resonance (NMR) spectroscopy is an
established technique for the study of enzyme kinetics that
has been used to characterise different enzyme systems in-
cluding (but not limited to) carbohydrate-processing en-
zymes,23,24 enzymes related to antibiotic resistance25 and
oxygenases.26,27 1H NMR spectroscopy enables the direct
monitoring of reaction kinetics in real time and accurate,
quantitative information can be obtained by following
changes in the peak area of the resonances associated with
the substrate and/or reaction productĲs). In contrast, thermal
shift assay is a simple and high-throughput method that can
be used to study protein–ligand binding interactions by mea-
suring the melting temperature of a protein by the use of a
fluorescence dye that is sensitive to changes in hydrophobic
environment.28–30 When a protein unfolds, it exposes its hy-
drophobic core. This enables the dye to bind to the exposed
hydrophobic regions, which lead to fluorescence. Ligand
binding may stabilise or destabilise the protein towards
Fig. 1 (a) Isocitrate lyase catalyses the conversion of isocitrate to glyoxylate and succinate; (b) 1H NMR spectroscopy to monitor ICL1-catalysed
turnover of isocitrate into succinate; (c) corresponding plot of the isocitrate turnover data. The curve was added to aid visualisation. Sample
contained 190 nM ICL1, 1 mM DL-isocitrate, 5 mM MgCl2 and 50 mM Tris/Tris-D11 (pH 7.5) in 90% H2O and 10% D2O. The hashtag (#) indicates Tris/
Tris-D11 peak. The errors shown are the standard deviation from three separate measurements.
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thermal denaturation, leading to a positive or negative shift
in the protein's melting temperature.31,32 We reasoned that a
strategy that combined 1H NMR spectroscopy and a thermal
shift assay would provide a good way to accurately monitor
ICL kinetics and inhibition. By using M. tuberculosis ICL1 as
a model system, we have optimised the experimental condi-
tions and demonstrated the feasibility of applying a joint
NMR and thermal shift strategy for inhibitor screening, inhi-
bition constant (IC50) measurement and for elucidating the
modes of action of ICL inhibitors. Finally, this technique is
exemplified by work in tandem with virtual high-throughput
screening, which subsequently led to the discovery of several
novel ICL1 inhibitors. ICL2 was not used in this study be-
cause it was reported to be unstable in vitro17 and it pos-
sesses relatively low catalytic activity when compared to
ICL1.12
Results and discussion
ICL1 enzyme kinetics by 1H NMR
We first tested the use of 1H NMR spectroscopy to monitor
the ICL1-catalysed turnover of isocitrate to succinate and
glyoxylate. DL-Isocitrate, which is available commercially, was
used as the substrate. MgCl2 was added to the reaction mix-
ture as it was previously shown to be important for ICL1 ac-
tivity.17 1H spectra were recorded at ∼1.3 minute intervals.
Upon addition of the enzyme, the peaks corresponding to iso-
citrate dropped in intensity, which was accompanied by the
appearance of a new singlet peak at 2.3 ppm, corresponding
to succinate (Fig. 1b). Integration of the isocitrate and succi-
nate peaks showed that the reaction appeared to slow down
when ∼50% of the isocitrate was consumed (Fig. 1c). As the
isocitrate was a racemic mixture, this result infers that ICL1
has a preference for one enantiomer, which is in agreement
with a previous study that showed D-isocitrate is the preferred
substrate of the enzyme.33
Divalent metals play important role in the activity of ICL1.
Previous studies showed that Mg2+ (and to a lesser extent,
Mn2+) are required for optimal ICL1 activity.17,34 In order to
confirm the concentration of divalent magnesium that is re-
quired for optimal activity of the enzyme, the reaction was
run using different concentrations of MgCl2. Under our reac-
tion conditions, 500 μM of MgCl2 was required for the opti-
mal activity (Fig. S1†). At least 500 μM of MgCl2 was used in
all subsequent kinetic and inhibition assays.
The kinetic parameters for ICL1 with DL-isocitrate were
then evaluated by 1H NMR. The Michaelis constant (KM) was
found to be 290 ± 10 μM and the catalytic constant (kcat) was
determined to be 4.3 ± 0.1 s−1 (Fig. S2†). These values were
similar to those obtained by Gould et al. using the aforemen-
tioned LDH assay, which were 190 μM and 5.24 s−1 respec-
tively (Table 1).12 The slight discrepancy between the two
measurements is likely due to differences in the reaction con-
ditions. Overall, this validated the accuracy of our 1H NMR
assay to study ICL1 kinetics.
We then tested the use of 1H NMR spectroscopy to moni-
tor the ICL1-catalysed turnover of methylisocitrate to pyruvate
and succinate (Fig. S3a†). (2S,3R)-2-Methylisocitrate was used
as substrate. In the presence of ICL1 and Mg2+, two new
singlet signals at ∼2.3 ppm, one corresponded to succinate
and the other corresponded to pyruvate, were found to in-
crease in intensity over time (Fig. S3b†). This was coupled
with a drop in intensity of the methylisocitrate signals. We
then repeated the experiments at different methylisocitrate
concentrations. Interestingly, substrate inhibition was ob-
served when methylisocitrate concentration exceeded 1 mM
(Fig. S4†). Substrate inhibition was not observed when iso-
citrate was used as substrate. Further investigations are re-
quired to fully understand the biological significance of these
observations. Overall, our results showed that 1H NMR
spectroscopy is a versatile and informative tool to study ICL1
kinetics that allows the use of different substrates and en-
ables kinetic information to readily be measured and
quantified.
Inhibition studies of ICL1 by 1H NMR
We then applied our new NMR-based assay to study ICL1 in-
hibition. Initially, we chose four known ICL inhibitors, in-
cluding three so-called first generation inhibitors itaconic
acid,35 3-nitropropionate36 and 3-bromopyruvate.37 Itaconic
acid and 3-nitropropionate are noncovalent inhibitors of ICL1
whereas 3-bromopyruvate inhibits ICL1 in a covalent manner.
Methyl 4-(4-methoxyphenyl)-4-oxobut-2-enoate, an inhibitor
that was discovered last year by Liu et al. using high-
throughput screening, was also evaluated (Table 2).38
Single concentration inhibition experiments were first
conducted (Fig. S5†). In agreement with previous studies,17
our 1H NMR assay showed that 3-nitropropionate was the
most potent inhibitor amongst 3-nitropropionate,
3-bromopyruvate and itaconic acid. Under our assay condition,
methyl 4-(4-methoxyphenyl)-4-oxobut-2-enoate was the weakest
of the four tested. We then repeated our measurements at
different inhibitor concentrations in order to obtain quantita-
tive inhibition information (IC50; Table 2 and Fig. S6–S9†).
The IC50 values of 3-nitropropionate, 3-bromopyruvate,
itaconic acid and methyl 4-(4-methoxyphenyl)-4-oxobut-2-
enoate were found to be 14.7 ± 1.8 μM, 17.5 ± 1.0 μM, 29.4 ±
4.1 μM and 250 ± 7 μM respectively. The reported IC50 value
for methyl 4-(4-methoxyphenyl)-4-oxobut-2-enoate was 30.9
μM.38 The slight discrepancy in our measured and reported
Table 1 Kinetic parameters of ICL1 with DL-isocitrate as substrate. Mea-
surements were made using samples contained 190 nM ICL1, varying
concentration of DL-isocitrate, 5 mM MgCl2 and 50 mM Tris/Tris-D11 (pH
7.5) in 90% H2O and 10% D2O. The errors shown are the standard devia-
tion from three separate measurements
KM/μM kcat/s
−1
This study 290 ± 10 4.3 ± 0.1
Gould et al.12 190 5.24
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IC50 values for methyl 4-(4-methoxyphenyl)-4-oxobut-2-enoate
is likely due to the different reaction conditions and assays
used in the two studies. Overall, our results show that
1H NMR is a useful tool to study ICL1 inhibition in vitro, en-
abling a rapid evaluation of inhibitor strength as well as pro-
viding quantitative information such as IC50.
Thermal shift assay to study ICL1-inhibitor interactions
Although 1H NMR spectroscopy was found to be a useful
method to study ICL1 inhibition, it is relatively low through-
put and labour intensive. A high throughput assay is needed
to facilitate the efficient screening and development of new
ICL inhibitors. Thermal shift assays are a widely-used
method to study protein–ligand interactions.28–30 The princi-
ple of a thermal shift assay is based on the premise that li-
gand binding can stabilise or destabilise protein to thermal
denaturing, and therefore lead to a shift in the protein's
melting temperature.
First, the melting temperature of ICL1 was measured. As
MgCl2 is important for the activity of the enzyme, a saturat-
ing concentration of 1 mM was used. The melting tempera-
ture of ICL1 in the presence of MgCl2 was found to be 43.0
°C. Next, the melting temperatures of ICL1 in the presence of
a saturating concentration (1 mM) of the aforementioned in-
hibitors and MgCl2 were measured. Addition of
3-bromopyruvate or itaconic acid were found to stabilise
ICL1, with positive shifts to melting temperatures of 52.5 °C
and 53.3 °C respectively. Interestingly, 3-nitropropionate and
methyl 4-(4-methoxyphenyl)-4-oxobut-2-enoate were found to
destabilise the protein, with negative thermal shifts to 40.9
°C and 37.6 °C respectively (Fig. S10†).
A negative thermal shift upon ligand binding has been
previously observed for other protein systems.31,32 A positive
thermal shift may be observed if the ligand induces the pro-
tein to adapt a more stable ‘closed’ conformation, whilst neg-
ative thermal shift may be observed if the ligand keeps the
protein in a less stable ‘open’ conformation. Previous struc-
tural studies by Sharma et al. showed that ICL1 may undergo
a two-step conformation change upon substrate binding
(Fig. S11†).39 Indeed, a crystal structure of ICL1 in the
presence of both 3-nitropropionate and glyoxylate was
found to adapt a ‘closed’ conformation (PDB id: 1F8I).
3-Nitropropionate is a structural analogue of succinate.36 We
reasoned that the binding of 3-nitropropionate on its own
may keep ICL1 in the open conformation in order to allow
Table 2 IC50 values of ICL1 inhibitors with DL-isocitrate as substrate. Measurements were made using samples contained 190 nM ICL1, 1 mM
DL-isocitrate, 5 mMMgCl2, varying concentration of inhibitor and 50 mM Tris/Tris-D11 (pH 7.5) in 90% H2O and 10% D2O. The errors shown are the standard
deviation from three separate measurements. Compounds 29 and 38 were obtained by virtual high-throughput screening (see Fig. S12–S14)
Inhibitor Structure IC50/μM
3-Nitropropionate 14.7 ± 1.8
3-Bromopyruvate 17.5 ± 1.0
Itaconic acid 29.4 ± 4.1
Methyl-4-(4-methoxyphenyl)-4-oxobut-2-enoate 250 ± 7
Compound 29 >100
Compound 38 >100
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glyoxylate to bind. However, in the presence of both
3-nitropropionate and glyoxylate, the protein can then un-
dergo conformational change to the ‘closed’ conformation,
as suggested by the crystal structure, to catalyse the reverse
reaction. This proposal is consistent with the mechanism
suggested by Sharma et al.39 It should also be noted that
binding of 3-nitropropionate or methyl 4-(4-methoxyphenyl)-4-
oxobut-2-enoate may induce a change in the oligomeric state
of ICL1, which exists as a tetramer in solution.39 However,
based on evidence from X-ray crystallography39 and molecu-
lar docking,38 both compounds are not known to bind at the
oligomerisation interface between the ICL1 monomers, or
interfere with the residues that were previously identified as
important for the protein's oligomerisation.40
Application of the combined 1H NMR and thermal shift
assays with virtual high-throughput screening
Virtual high-throughput screening is a cost-effective and effi-
cient strategy to identify chemical structures that are poten-
tially important for binding to a target protein.41–43 Obvi-
ously, the hits identified by virtual high-throughput
screening needed to be verified experimentally. In order to
test the applicability of the 1H NMR and thermal shift assays
and to identify new inhibitors of ICL1, a virtual screen was
conducted. Using the crystal structure of ICL1 (PDB ID: 1F8I,
resolution 2.25 Å),39 a screen was performed with the Inter-
BioScreen Ltd natural product collection.44 9050 compounds
were screened and four different scoring functions, including
GoldScore (GS),45 ChemScore (CS),46,47 Piecewise Linear
Potential (ChemPLP)48 and Astex Statistical Potential (ASP),49
were used. Ten docking runs were allowed for each com-
pound with virtual screening setting (30%). Based on the
scores, ligands with predicted low GS (<45), CS (<20),
ChemPLP (<45), ASP (<20) as well as those with no hydrogen
bonding (HB = 0) were eliminated, which resulted in 840
compounds. These compounds were screened again with
high search efficiency (100%) and fifty docking runs. Candi-
dates with low GS (<38), CS (<17), ChemPLP (<38), ASP
(<17) as well as those with predicted limited hydrogen bond-
ing (HB < 1) were eliminated, resulting in 205 candidates.
For both rounds of screening the cut-off values of the scores
were determined based on the scores of the known inhibitors
itaconic acid, 3-nitropropionate and 3-bromopyruvate. Fur-
thermore, only compounds with predicted hydrogen bonding
were taken forward since hydrogen bond is important not
only for the affinity but also the specificity of the ligand bind-
ing.50 These candidates were then visually inspected for con-
sensus of the best predicted configuration of the ligands be-
tween the scoring functions. Ligands that showed plausible
configurations, i.e., not strained, lipophilic moieties not
pointing into the water environment resulting in an entropy
penalty, were taken forward. Furthermore, compounds that
did not contain undesirable moieties that are linked to gen-
eral cell toxicity (e.g. thiourea and aliphatic ketones) and
chemical reactivity (e.g. Michael acceptors and imines), were
chosen.51,52 This screening methodology has been success-
fully applied previously to find active ligands for various bio-
molecular systems.53–56 In total, 41 compounds were selected
for experimental testing (Fig. S12 and Table S1†).
We then applied the 1H NMR and thermal shift assays to
verify the hits obtained from the virtual screen. First, we
tested the compounds using the thermal shift assay. Out of
the 41 compounds, 19 induced a shift of more than 0.5 °C
(positive or negative) in the melting temperature of ICL
(Fig. S13†). This was followed with 1H NMR-based single
concentration inhibition experiment to test the 19 hits. The
result showed that two molecules significantly inhibited
ICL1 (compounds 29 and 38, Fig. S14†). The IC50 of the
molecules were both >100 μM (Fig. S15 and S16† and
Table 2). Molecular modelling suggests compounds 29 and
38 both occupy the substrate and Mg2+ binding sites. The
reason for the relatively low IC50 values is due to the re-
moval of the Mg2+ ion from the binding pocket upon inhib-
itor binding. Mg2+ sits within a cavity that is predicted to be
occupied by aliphatic moieties of the inhibitors. Thus, the in-
hibitors need to displace the magnesium ion to bind effi-
ciently, which would require a considerable energy expendi-
ture due to the saturation concentration (5 mM) of the ion
in the experimental setup. The main stream molecular de-
scriptors (molecular weight, log P, hydrogen bond donors/ac-
ceptors, polar surface area and rotatable bonds see Table
S2†) for compounds 29 and 38 were calculated and they
conform to drug-like chemical space except log P and num-
bers of hydrogen bond donors, which are in lead-like chemi-
cal space (for the definition of chemical space see ref. 57).
Furthermore, the molecular weight for the hits is in the low
to mid 300s, making them excellent starting points for
chemical modification and further development. Finally,
nine close structural derivatives were purchased to generate
a structural activity (SAR) profile (Fig. S17†), but none
showed any activity. In general, docking to the binding site
showed that these compounds are too bulky to fit into it.
Overall, our results show that combining 1H NMR and ther-
mal shift assays is an effective strategy for screening poten-
tial ICL1 inhibitors.
Conclusions
ICL isoforms 1 and 2 are important enzymes for the survival
of M. tuberculosis in macrophages, enabling the bacteria to
utilise fatty acids and cholesterol as carbon sources. ICLs
are attractive inhibition targets for the treatment of latent
TB. By using ICL1 as a model system, we have demon-
strated the general applicability of a combined 1H NMR and
thermal shift assays to screen for and evaluate ICL inhibi-
tors. Both methods presented herein are relatively simple to
carry out. In contrast to current fluorescence-based assays
that rely on enzyme or chemically coupled reactions, the
NMR assay described herein enables a direct observation of
substrate consumption and product formation and is there-
fore less prone to errors. One minor drawback of the NMR
MedChemComm Research Article
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assay is the low throughput associated with monitoring re-
actions in real time. Typically, around 15 to 20 minutes of
measurement time (six to eleven 1H experiments) were
needed to obtain an initial rate. This equates to around
seven hours of total measurement time to obtain a full ki-
netic analysis or a complete IC50 curve with, for example,
six concentration points in triplicate. In contrast, the ther-
mal shift assay is a high-throughput method enabling semi-
automatic measurements using multi-well plates. Ligand
binding to ICL1 was easily identified through a change in
the protein's melting temperature. Interestingly, we observed
both positive (i.e. stabilising) and negative (i.e. destabilising)
thermal shifts of ICL1 with four known inhibitors, likely
due to the inhibitors keeping ICL1 in either the open or
closed conformations. We have demonstrated the utility of
these assays by validating a small library of compounds that
were obtained by a virtual high-throughput screen. This ulti-
mately led to the discovery of two novel ICL1 inhibitors that
are the subject of ongoing medicinal chemistry studies in
our laboratories.
Experimental section
Materials
Unless otherwise stated, all chemicals were purchased from
Sigma-Aldrich/Merck, Thermo Fisher Scientific, Environmen-
tal Control Products (ECP), AK Scientific, Global Science – a
VWR/Bio-Strategy Company and Bio-Rad. Tris-D11 and D2O
were from Cambridge Isotope Laboratories or Cortecnet. Re-
striction enzymes BasI-HF and T4 DNA polymerase were
obtained from New England Biolabs. Competent cells XL10-
Gold and BL21 (DE3) were obtained from Agilent. The Bio-
Rad Precision Plus Protein Kaleidoscope Prestained Protein
Standards were used for sodium dodecylsulphate polyacryl-
amide gel electrophoresis (SDS-PAGE). Methyl 4-(4-methoxy-
phenyl)-4-oxobut-2-enoate was obtained from Enamine. Com-
pounds from virtual screening were obtained from
InterBioScreen.
Cloning of ICL1
Synthetic gene (gBlocks) encoding M. tuberculosis ICL1 (Table
S3†) were obtained from Integrated DNA Technologies. The
pNIC28-Bsa4 vector was a gift from Opher Gileadi (Addgene
plasmid #26103).58 In order to clone onto the pNIC28-Bsa4
vector, the tacttccaatccatg sequence was added to the 5′ end
and taacagtaaaggtggata was added to the 3′ end of the DNA
sequence encoding M. tuberculosis ICL1 (Table S3†) when de-
signing the synthetic gene. The synthetic gene and the
pNIC28-Bsa4 vector were prepared and cloned using the pro-
cedure reported by Gileadi et al. with XL10-Gold.59 The re-
combinant plasmid was confirmed by DNA sequencing (DNA
Sequencing Centre, The University of Auckland). The correct
plasmid were then used to transform BL21 (DE3) competent
cells for protein expression.
Production and purification of ICL1
The recombinant plasmid was first transformed in E. coli
BL21(DE3). Starter culture was incubated overnight at 37 °C
with shaking in 2YT media. The starter culture was then di-
luted with fresh 2YT media, which was then incubated at
37 °C with shaking until OD600 of 0.6. Isopropyl-β-D-
thiogalactopyranoside (IPTG; 200 μM final concentration) was
then added and further incubated at 18 °C with shaking for a
further 16 to 20 hours. Cells were harvested by centrifuga-
tion. Cell pellets were obtained by centrifugation and
resuspended in 50 mM HEPES buffer pH 7.8 with 5 mM im-
idazole and 500 mM NaCl. The cells were lysed on ice by son-
ication (4 × 20 seconds) burst at 60% amplitude with 40 sec-
onds rest in between. The protein was purified by 5 mL
His-trap column eluting with Tris-HCl buffer pH 7.8 with
500 mM imidazole and followed by gel filtration using
50 mM Tris-HCl buffer pH 7.5.
Thermal shift assay
Thermal shift assay was carried out using a BioRad MyiQ real
time PCR instrument. The assay was carried out using 20 μM
ICL1, 1 mM compounds and 1 mM MgCl2 in 50 mM Tris-HCl
pH 7.5. Protein unfolding was monitored by measuring the
fluorescence of the SYPRO Orange dye. The dye stock (5000×
concentrate) was first diluted in 50 mM Tris-HCl (pH 7.5) to
a 200× concentrate before diluting by 5 times into the sam-
ple. Temperature was increased from 25 to 95 °C at 1 °C in-
crement every 60 seconds. All measurements were performed
in triplicate. For determination of protein melting tempera-
ture values, melting curve for each data set was analysed by
SigmaPlot 13 (USA) and fitted with the Sigmoid, 3 parameter
model.
NMR experiments
NMR experiments were conducted at a 1H frequency of 500
MHz using a Bruker Avance III HD spectrometer equipped
with a BBFO probe. Experiments were conducted at 300 K.
Standard 5 mm NMR tubes (Wilmad) using a sample volume
of 500 μL were used in all experiments. The pulse tip-angle
calibration using the single-pulse nutation method (Bruker
pulsecal routine) was undertaken for each sample.60 All mea-
surements were performed in triplicate.
Time course experiments were monitored by standard
Bruker 1H experiments with water suppression by excitation
sculpting. Unless otherwise stated, the number of transients
was 16, and the relaxation delay was 2 seconds. The lag time
between addition of enzyme and the end of the first experi-
ment was usually 4 minutes. Initial rates were calculated by
linear fitting using Excel 2013 (Microsoft) for data points up
to 20% turnover. Kinetic parameters were obtained using the
Hanes plot. Linear fitting was done using Excel 2013 (Micro-
soft). All NMR samples contained 190 nM ICL1, 1 mM DL-
isocitrate and 5 mM MgCl2 buffered with 50 mM Tris-D11 (pH
7.5) in 90% H2O and 10% D2O. For kinetic parameter mea-
surements, the isocitrate concentrations ranged from 50 μM
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to 750 μM. For single concentration inhibition assay, 100 μM
inhibitors was used. For IC50 measurements, varying concen-
trations of inhibitors were used. IC50 values were obtained by
SigmaPlot 13 and fitted with the Sigmoid, 3 parameter model.
Virtual high throughput screening
The compounds were docked to the crystal structure of ICL I
(PDB ID: 1F8I),39 which was obtained from the Protein Data
Bank (PDB).61,62 The Scigress version FJ 2.6 program
(Scigress: Version FJ 2.6; Fijitsu Limited, 2008–2016) was
used to prepare the crystal structure for docking, i.e., hydro-
gen atoms added, the co-crystallised succinic acid and
glyoxylic acid were removed from protein, the magnesium
ion as well as crystallographic water molecules. The Scigress
software suite was also used to transfer the structures from
2D to 3D followed by structural optimisation using the MM2
force field.63 The centre of the binding was defined on the
co-crystallised ligand with coordinates (x = 5.931, y = 56.950,
z = 83.843) with 10 Å radius. For the initial screen 30% search
efficiency was used (virtual screen) with ten runs per com-
pound. For the second phase (re-dock) 100% efficiency was
used in conjunction with fifty docking runs. The GoldScore,45
ChemScore,46,47 ChemPLP48 and ASP49 scoring functions
were implemented to validate the predicted binding modes
and relative energies of the ligands using GOLD v5.2 software
suite. The InterBioScreen Ltd natural product collection was
used for the screening.44 The robustness of the protocol was
tested by re-docking the co-crystallised ligand (succinic acid)
with these results: RMSD (root-mean-square deviation) GS –
1.750 Å, CS – 0.929 Å, PLP – 0.747 Å and ASP – 1.882 Å, verify-
ing the validity of the procedure. The QikProp v3.21 (QikProp
v3.2, Schrödinger, New York, 3.2, 2009) software package was
used to calculate the molecular descriptors of the com-
pounds. The reliability of the prediction power of QikProp is
established for the molecular descriptors used in this
study.64
Synthesis of (2S,3R)-2-methylisocitrate
(2S,3R)-2-Methylisocitrate was prepared according to the pro-
cedure reported by Darley et al.65
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